Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01026727 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy
A Phase 2 study, sponsored by Myrexis.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01026727: Clinical Trial Phase 2 study, sponsored by Myrexis.
NCT01026727 is a Phase 2 study that was terminated before completion, run by Myrexis. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01026727, a Phase 2 study, was terminated before completion, sponsored by Myrexis.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This phase 2b study is designed to assess the long-term efficacy (24 weeks) of MPC-4326 in combination with a 2-3 drug optimized background regimen (OBR) relative to the efficacy of a 3-4 antiretroviral (ARV) regimen in treatment experienced, HIV-1 infected subjects.
Interventions
- DRUG MPC-4326 plus a 2-3 drug optimized background regimen (OBR)
- DRUG 3-4 commercially available antiretroviral drugs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2009-11 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Why NCT01026727 stopped before completion
NCT01026727 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which MPC-4326 plus a 2-3 drug optimized background regimen (OBR) is the first listed.
NCT01026727 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01026727 about?
NCT01026727 is a clinical study titled "A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy". This phase 2b study is designed to assess the long-term efficacy (24 weeks) of MPC-4326 in combination with a 2-3 drug optimized background regimen (OBR) relative to the efficacy of a 3-4 antiretroviral (ARV) regimen in treatment experienced, HIV-1 infected subjects.
What is the current status of trial NCT01026727?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2009-11. Estimated completion is 2010-06.
What interventions are being tested in trial NCT01026727?
The interventions under investigation include: MPC-4326 plus a 2-3 drug optimized background regimen (OBR) (DRUG), 3-4 commercially available antiretroviral drugs (DRUG).
Who is sponsoring clinical trial NCT01026727?
This trial is sponsored by Myrexis, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01026727's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia